TL;DR
This meta-analysis systematically reviews the long-term safety and efficacy of single-fraction high-dose-rate brachytherapy (SFHDR-BT) for localized prostate cancer. The findings suggest SFHDR-BT is generally well-tolerated with low toxicity rates, but its clinical benefit may be suboptimal, necessitating further high-quality prospective studies.
What Problem Does This Paper Address?
Prostate cancer treatment often involves radiation therapy, with brachytherapy offering a way to deliver higher doses directly to the tumor. While multi-fraction high-dose-rate brachytherapy (HDR-BT) is established, it comes with drawbacks like multiple hospital visits and extended recovery. Single-fraction HDR-BT (SFHDR-BT) emerged as a potentially more convenient alternative, but robust evidence on its long-term outcomes, especially safety and efficacy, has been lacking. This paper aims to fill that gap by systematically analyzing existing studies to provide a comprehensive overview of SFHDR-BT's performance.
Methods
The researchers conducted a systematic literature search across PubMed, Embase, and the Cochrane Library databases, adhering to PRISMA guidelines. They included studies on localized prostate cancer treated with SFHDR-BT, requiring a minimum follow-up of five years. The primary endpoints were safety (toxic effects like gastrointestinal and genitourinary issues, and sexual dysfunction) and efficacy (biochemical recurrence-free survival - bRFS, and overall survival - OS). They used proportion rates and 95% confidence intervals to measure effect. For quality assessment, they employed the Jadad scale for randomized controlled trials and the MINORS tool for non-randomized studies. Statistical analysis involved quantifying incidence rates, using forest plots, and assessing heterogeneity with Cochran's Q test and the Higgins I² statistic. Random-effects models were used when heterogeneity was significant, and fixed-effects models otherwise. Publication bias was assessed using Begg's funnel plot.
Datasets
This paper is a meta-analysis, meaning it synthesizes data from existing published studies. It does not introduce new datasets or benchmarks. The data is derived from eight eligible studies that met the inclusion criteria, encompassing a total of 552 patients.
Key Insights and Ideas
- Convenience vs. Efficacy Trade-off: SFHDR-BT offers significant advantages in terms of treatment convenience (single session, shorter recovery) compared to multi-fraction HDR-BT. However, the results suggest this convenience might come at the cost of potentially "suboptimal clinical benefit," particularly regarding long-term biochemical control.
- Low Acute Toxicity is Promising: The near-zero incidence of severe gastrointestinal toxicity and a low rate of severe genitourinary toxicity are encouraging findings, suggesting SFHDR-BT is a safe option in terms of immediate side effects.
- Sexual Dysfunction Remains a Concern: While severe sexual dysfunction is relatively low (4%), the incidence of grade 2 sexual dysfunction is considerably higher (30%), with erectile dysfunction being the primary manifestation. This highlights the need for careful patient counseling and management of long-term quality of life.
- bRFS is Moderate, OS is High: The meta-analysis shows a respectable but not outstanding long-term bRFS of 72%, while overall survival remains very high at 90%. This suggests SFHDR-BT can effectively manage the disease for many, but there's room for improvement in preventing recurrence.
- Need for High-Quality Prospective Trials: The authors repeatedly emphasize the need for more rigorous, well-designed prospective studies to definitively confirm the safety and efficacy of SFHDR-BT, especially given the limitations of the current evidence base (e.g., inclusion of retrospective studies).
Key Results
- Severe GI Toxicity: 0% cumulative incidence.
- Severe GU Toxicity: 3% cumulative incidence (95% CI 1-5%).
- Severe Sexual Dysfunction: 4% cumulative incidence (95% CI 1-7%).
- Grade 2 Sexual Dysfunction: 30% cumulative incidence (95% CI 17-43%).
- Long-term bRFS (5-6 years): 72% (95% CI 68-76%).
- Long-term OS (5-6 years): 90% (95% CI 85-95%).
- The study included 8 studies with a total of 552 patients, with a median follow-up of 71.3 months.
Limitations and Future Work
The authors acknowledge several limitations:
- Inclusion of Retrospective Studies: The meta-analysis included a limited number of retrospective studies, which can introduce bias in data aggregation.
- Limited Number of Studies: The overall number of studies and patients, while meeting inclusion criteria, is not vast, especially for long-term outcomes.
- Patient Demographics: The cohort was predominantly Caucasian, limiting the generalizability of findings to diverse ethnic groups.
Future work should focus on:
- High-Quality Prospective Studies: The most crucial recommendation is the need for more rigorously structured, prospective clinical trials to validate SFHDR-BT's safety and efficacy.
- Optimizing Treatment Strategies: Further research could explore integrating local boosts with SFHDR-BT at the lesion site to address localized failures.
- Understanding Tumor Heterogeneity: Investigating how tumor cell resistance mechanisms, like those in cancer stem cells, and tumor heterogeneity impact SFHDR-BT effectiveness is important.
- Patient Selection: Refining patient selection criteria for SFHDR-BT is essential, particularly considering risk stratification.
Summary updated